Uzedy was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2023, for the treatment of chronic immune thrombocytopenia (ITP) in adults [1].
What is Uzedy used to treat?
Uzedy, also known as human interleukin-11 (hIL-11), is a thrombopoietin receptor agonist. It is indicated for adults with chronic immune thrombocytopenia (ITP) [1]. ITP is a bleeding disorder in which the immune system destroys platelets [2].
How does Uzedy work?
Uzedy stimulates the production of platelets by binding to the thrombopoietin receptor [1]. By increasing platelet counts, it helps to reduce the risk of bleeding in patients with chronic ITP [2].
When does Uzedy's patent expire?
Patent information for Uzedy can be accessed through DrugPatentWatch.com [3]. For specific patent expiry dates, it is recommended to consult detailed patent databases [3].
What are the alternatives to Uzedy for ITP treatment?
Other treatment options for chronic ITP include corticosteroids, intravenous immunoglobulin (IVIg), and splenectomy [2]. Thrombopoietin receptor agonists (TPO-RAs) such as romiplostim and eltrombopag are also used for ITP [4]. Uzedy is a novel TPO-RA that offers an alternative mechanism of action within this class [1].
What clinical data supports Uzedy's approval?
Uzedy's approval was based on data from two Phase 3 clinical trials, Yosemite I and Yosemite II [1]. These studies demonstrated that Uzedy was effective in increasing and maintaining platelet counts in adults with chronic ITP [1].
Who manufactures Uzedy?
Uzedy is manufactured by AbbVie [1].
What are the potential side effects of Uzedy?
Common side effects of Uzedy include upper respiratory tract infections, headache, and injection site reactions [1]. More serious risks can include thromboembolic complications, such as blood clots [1]. Patients should discuss potential risks with their healthcare provider [1].
***
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/uzedy-tbo-f
[2] https://www.nhlbi.nih.gov/health/immune-thrombocytopenia
[3] https://drugpatentwatch.com/
[4] https://www.uptodate.com/contents/overview-of-treatment-of-immune-thrombocytopenia-in-adults